Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron

Executive Summary

In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews

You may also be interested in...



With Streamlined Pipeline, Next Steps For Sanofi R&D Include Full Reorg

Sanofi Aventis has already cut 14 projects from its pipeline since February, but there could be more coming by the end of the year - and with a possible Plavix successor among the compounds in limbo, those decisions will be a true test of whether Sanofi is really going to steer clear of "me-too" type products that may be a tougher commercial climb

With Streamlined Pipeline, Next Steps For Sanofi R&D Include Full Reorg

Sanofi Aventis has already cut 14 projects from its pipeline since February, but there could be more coming by the end of the year - and with a possible Plavix successor among the compounds in limbo, those decisions will be a true test of whether Sanofi is really going to steer clear of "me-too" type products that may be a tougher commercial climb

Sanofi Cuts Development Of 14 Drugs In First Quarter, With More R&D Changes To Come

Among halted development programs is Phase III antidepressant saredutant; decision on Plavix follow-on idrabiotaparinux awaits FDA safety determination.

Related Content

UsernamePublicRestriction

Register

PS049979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel